Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
30605747
DOI
10.1016/j.ijbiomac.2018.12.128
PII: S0141-8130(18)35018-9
Knihovny.cz E-resources
- Keywords
- Active targeting, Biocompatibility, Cancer nanomedicine,
- MeSH
- Apoptosis drug effects MeSH
- Biocompatible Materials pharmacology MeSH
- Cell Death drug effects MeSH
- Clone Cells MeSH
- Endocytosis drug effects MeSH
- Ferritins metabolism MeSH
- Coordination Complexes chemical synthesis chemistry pharmacology MeSH
- Folic Acid pharmacology MeSH
- Humans MeSH
- Ligands MeSH
- Cell Line, Tumor MeSH
- Nickel pharmacology MeSH
- Cell Movement drug effects MeSH
- Cell Proliferation drug effects MeSH
- Iron-Binding Proteins metabolism MeSH
- Receptors, Cell Surface metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biocompatible Materials MeSH
- ferritin receptor MeSH Browser
- Ferritins MeSH
- Coordination Complexes MeSH
- Folic Acid MeSH
- Ligands MeSH
- Nickel MeSH
- Iron-Binding Proteins MeSH
- Receptors, Cell Surface MeSH
Metal-based coordination compounds, including the well-known cytostatic drug cisplatin, are widely used in the anticancer therapy. Generally, they exhibit high cytotoxicity not only towards malignant cells, but also towards non-malignant cells, which represents main problem of their clinical use. Herein, we describe the synthesis, characterization and biological testing of three trinuclear nickel(II) coordination compounds. Central nickel atoms are bridged by trithiocyanurate anion and coordinated by triamine and bis-benzimidazoles, respectively. To delineate a potential usage in anticancer therapy, we encapsulated the most cytotoxic complex into biomacromolecular protein cage apoferritin (FRT), forming FRTNi. FRT encapsulation markedly decreased the hemotoxicity of free Ni compounds. Despite FRTNi can be internalized through passive targeting by enhanced permeability and retention effect, we further introduced active targeting utilizing folate receptor (FR) via folic acid (FA)-modified FRT (FRTNiFA). Using breast cancer cell lines T-47D (FR+), MCF-7 (FR-) and non-malignant mammary gland derived cell line HBL-100 (FR-), we show pronounced FR-dependent internalization of FRTNiFA. Overall, we demonstrate that the FRT macromolecular nanocarrier provides a very low off-target toxicity, which could enable the use of highly toxic Ni compounds in cancer nanomedicine.
References provided by Crossref.org